Decoding the bone marrow microenvironment in Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) remains one of the most challenging cancers to treat, especially in elderly patients. Resistance to treatment often stems from the bone marrow (BM) microenvironment, a complex network of immune and stromal cells that fosters tumor survival and shields it from therapy. The TALETE project is at the forefront of efforts to decode this intricate environment. By studying AML patients undergoing treatment with azacitidine and venetoclax, we aim to identify the key cellular players and pathways that contribute to this resistance.

Using state-of-the-art technologies like proteomics, single-cell RNA sequencing, and metabolic profiling, TALETE researchers are exploring the behavior of immune cells, including Tregs, NK cells, and macrophages, alongside stromal cells such as mesenchymal stromal cells (MSCs). This comprehensive approach will provide unprecedented insights into how these cells interact and drive resistance.

By understanding the BM microenvironment’s role in AML progression, TALETE hopes to lay the groundwork for therapies that disrupt these resistance mechanisms. This could significantly improve outcomes for patients, particularly those with limited options.